A 42-year-old woman with known rheumatoid arthritis who had been clinically stabilized with methotrexate and sulphasalazine therapy provided serum specimens for follow-up estimation of her vitamin D levels. She had been previously diagnosed with VDD (25OHD, 12.5 ng/ mL; RI, 20 to 50 ng/mL) and was prescribed 60,000 IU of vitamin D3, to be taken once weekly for 6 weeks. Vitamin D levels, as measured by the Roche Cobas e411 (F. Hoffmann-La Roche Ltd., Basel, Switzerland) was 746 ng/mL (RI], 20 to 50 ng/mL). However, the levels of serum calcium (9.0 mg/dL [RI, 8.6 
A 42-year-old woman with known rheumatoid arthritis who had been clinically stabilized with methotrexate and sulphasalazine therapy provided serum specimens for follow-up estimation of her vitamin D levels. She had been previously diagnosed with VDD (25OHD, 12.5 ng/ mL; RI, 20 to 50 ng/mL) and was prescribed 60,000 IU of vitamin D3, to be taken once weekly for 6 weeks. Vitamin D levels, as measured by the Roche Cobas e411 (F. Hoffmann-La Roche Ltd., Basel, Switzerland) was 746 ng/mL (RI], 20 to 50 ng/mL). However, the levels of serum calcium (9.0 mg/dL [RI, 8.6 to 10.5 mg/dL]), magnesium (1.90 mg/dL; 1.8 to 2.6 mg/dL]) and phosphate (3.5 mg/ dL; 2.5 to 4.5 mg/dL]) were normal. When results from repeat specimens were similar, we considered assay interference and measured vitamin D levels with 2 other chemiluminescence techniques (VITROS Vitamin D [Ortho Clinical Diagnostics Inc., Raritan, NJ], 720 ng/ mL; and Abbott Architect 25OH vitamin D assay [Abbott Laboratories, Abbott Park, IL], 670 ng/mL), which yielded similar results. Plasma parathyroid hormone (PTH) levels, as measured using Roche Cobas e411, were suppressed, at 8.5 pg/mL (RI, 15 to 65 pg/mL). Other parameters such Vitamin D deficiency (VDD) is believed to be a global epidemic. 1 We observed no evidence of any aortic calcification or nephrolithiasis in abdominal imaging. X-ray images of the spine and hips were also normal; we did not perform dual X-ray absorptiometry (DEXA) scanning. The patient had been consuming a normal healthy Indian diet that provided her sufficient calcium. After probing questioning of the patient and review of her medical records, it became apparent that she had misinterpreted the intended weekly dose of vitamin D3 and had consumed 60,000 IU daily (rather than weekly) for the previous 4 months (rather than 6 weeks).
Discussion
In patients with VDT, clinical manifestations are a consequence of elevated calcium levels rather than metabolic forms of Vitamin D. 4 Vieth 5 has suggested that serum vitamin D levels need to be consistently greater than 150 ng/mL to produce hypercalcemia and other clinical manifestations of toxicity. However, the mystery in the clinical and laboratory results for our patient was the absence of hypercalcemia despite the marked elevation of plasma vitamin D. 
Mechanisms of Vitamin D Toxicity

Follow-Up of the Patient
Because the patient has normal calcium levels, no active management was undertaken. We asked her to immediately discontinue vitamin D supplementation and to maintain adequate hydration; we also recommended a calciumrestricted diet. In hypervitaminosis D, ingested vitamin D is deposited and, consequently, slowly released into body fat. 18 Hence, we advised our patient to undergo repeat testing of her serum vitamin D levels after 4 months.
Conclusions and Recommendations
Clinical trials of VDT with human volunteers are not possible for ethical reasons. Thus, the existing knowledge base of VDT has been built through case reports and animal experiments. This case study highlights that vitamin D metabolism is complex and that many aspects remain unknown. The possibilities that might have prevented hypercalcemia in this patient include elevated VDP leading to reduced bioavailable vitamin D, mutation in the VDR, and a hyperactive 24-hydroxylase. Generally, patients with severe VDT experience acute and dangerous hypercalcemia. Physicians need to consider the risk of medication errors while prescribing vitamin D supplementation. Critical alerts of vitamin D are relatively uncommon among laboratories. However, with the rise in VDT cases that Peerless Hospital has observed, its laboratory has formulated a policy of compulsory testing for serum calcium in all patients with vitamin D levels greater than 150 ng/mL. If calcium level results exceed 13 mg/dL, a critical alert is generated, with a comment on the report to discontinue vitamin D therapy or to evaluate possibility of surreptitious intake of multivitamin supplements rich in vitamin D. This case highlights the need to be vigilant for adverse effects of vitamin D supplementation and to maintain communication between laboratory and clinical personnel to prevent potentially dangerous incidents.
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